149 related articles for article (PubMed ID: 16491126)
21. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
22. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
23. Autophagy by ARF: a short story.
Sherr CJ
Mol Cell; 2006 May; 22(4):436-7. PubMed ID: 16713573
[TBL] [Abstract][Full Text] [Related]
24. Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye.
Silva RL; Thornton JD; Martin AC; Rehg JE; Bertwistle D; Zindy F; Skapek SX
EMBO J; 2005 Aug; 24(15):2803-14. PubMed ID: 16037818
[TBL] [Abstract][Full Text] [Related]
25. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor.
Rocha S; Campbell KJ; Perkins ND
Mol Cell; 2003 Jul; 12(1):15-25. PubMed ID: 12887889
[TBL] [Abstract][Full Text] [Related]
26. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
Eymin B; Gazzeri S; Brambilla C; Brambilla E
Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
[TBL] [Abstract][Full Text] [Related]
27. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
28. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
29. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
[TBL] [Abstract][Full Text] [Related]
30. AKT regulates NPM dependent ARF localization and p53mut stability in tumors.
Hamilton G; Abraham AG; Morton J; Sampson O; Pefani DE; Khoronenkova S; Grawenda A; Papaspyropoulos A; Jamieson N; McKay C; Sansom O; Dianov GL; O'Neill E
Oncotarget; 2014 Aug; 5(15):6142-67. PubMed ID: 25071014
[TBL] [Abstract][Full Text] [Related]
31. The ARF tumor suppressor: keeping Myc on a leash.
Gregory MA; Qi Y; Hann SR
Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
[TBL] [Abstract][Full Text] [Related]
32. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
[TBL] [Abstract][Full Text] [Related]
33. p53-independent functions of the p19(ARF) tumor suppressor.
Weber JD; Jeffers JR; Rehg JE; Randle DH; Lozano G; Roussel MF; Sherr CJ; Zambetti GP
Genes Dev; 2000 Sep; 14(18):2358-65. PubMed ID: 10995391
[TBL] [Abstract][Full Text] [Related]
34. ARF tumor suppression in the nucleolus.
Maggi LB; Winkeler CL; Miceli AP; Apicelli AJ; Brady SN; Kuchenreuther MJ; Weber JD
Biochim Biophys Acta; 2014 Jun; 1842(6):831-9. PubMed ID: 24525025
[TBL] [Abstract][Full Text] [Related]
35. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
[TBL] [Abstract][Full Text] [Related]
36. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.
Aslanian A; Iaquinta PJ; Verona R; Lees JA
Genes Dev; 2004 Jun; 18(12):1413-22. PubMed ID: 15175242
[TBL] [Abstract][Full Text] [Related]
37. Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway.
Ta VB; de Bruijn MJ; ter Brugge PJ; van Hamburg JP; Diepstraten HJ; van Loo PF; Kersseboom R; Hendriks RW
Blood; 2010 Feb; 115(7):1385-93. PubMed ID: 20008789
[TBL] [Abstract][Full Text] [Related]
38. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.
Carr J; Bell E; Pearson AD; Kees UR; Beris H; Lunec J; Tweddle DA
Cancer Res; 2006 Feb; 66(4):2138-45. PubMed ID: 16489014
[TBL] [Abstract][Full Text] [Related]
39. Arf induces p53-dependent and -independent antiproliferative genes.
Kuo ML; Duncavage EJ; Mathew R; den Besten W; Pei D; Naeve D; Yamamoto T; Cheng C; Sherr CJ; Roussel MF
Cancer Res; 2003 Mar; 63(5):1046-53. PubMed ID: 12615721
[TBL] [Abstract][Full Text] [Related]
40. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
Van Maerken T; Vandesompele J; Rihani A; De Paepe A; Speleman F
Cell Death Differ; 2009 Dec; 16(12):1563-72. PubMed ID: 19779493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
